Cargando…

Liver abnormalities in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickel, Nils P., Galura, Gian M., Zuckerman, Marc J., Hakim, M. Nawar, Alkhateeb, Haider, Mukherjee, Debabrata, Austin, Eric D., Heresi, Gustavo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544777/
https://www.ncbi.nlm.nih.gov/pubmed/34707859
http://dx.doi.org/10.1177/20458940211054304
Descripción
Sumario:Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure produces congestive hepatopathy, a disease state that has direct consequences on liver biochemistry, histology, and systemic glucose and lipid metabolism. This article aims to summarize the consequences of congestive hepatopathy with an emphasis on liver biochemistry, histology, and PAH-targeted therapy. Furthermore, PAH-specific changes in glucose and lipid metabolism will be discussed.